Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlfredoM617 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::47191740.png) Alfredo M [@AlfredoM617](/creator/twitter/AlfredoM617) on x XXX followers
Created: 2025-07-14 19:36:07 UTC

Viking $VKTX Is Not Just “Another GLP-1 Play”

Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has:

A dual-form GLP-1/GIP agonist that may be best-in-class

A NASH drug with market-leading data and lipid benefits

A rare disease candidate that could be first-in-class

$1B in cash, allowing it to go to market alone or with leverage

Strong clinical and mechanistic de-risking

Multiple paths to monetization, including partnership or M&A

In short, Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise, or become the most lucrative buyout in biotech this cycle. With key Phase X readouts coming and competitive scarcity increasing, the stock’s current price may soon look like a historical anomaly.


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944843369181561151/c:line.svg)

**Related Topics**
[1b](/topic/1b)
[$1b](/topic/$1b)
[$vik](/topic/$vik)
[$vktx](/topic/$vktx)

[Post Link](https://x.com/AlfredoM617/status/1944843369181561151)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

AlfredoM617 Avatar Alfredo M @AlfredoM617 on x XXX followers Created: 2025-07-14 19:36:07 UTC

Viking $VKTX Is Not Just “Another GLP-1 Play”

Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has:

A dual-form GLP-1/GIP agonist that may be best-in-class

A NASH drug with market-leading data and lipid benefits

A rare disease candidate that could be first-in-class

$1B in cash, allowing it to go to market alone or with leverage

Strong clinical and mechanistic de-risking

Multiple paths to monetization, including partnership or M&A

In short, Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise, or become the most lucrative buyout in biotech this cycle. With key Phase X readouts coming and competitive scarcity increasing, the stock’s current price may soon look like a historical anomaly.

XXXXX engagements

Engagements Line Chart

Related Topics 1b $1b $vik $vktx

Post Link

post/tweet::1944843369181561151
/post/tweet::1944843369181561151